Skip to main content
Jeffrey Skolnik, MD, Pediatric Hematology & Oncology, Philadelphia, PA, Children's Hospital of Philadelphia

JeffreyMSkolnikMD

Pediatric Hematology & Oncology • Philadelphia, PA

Physician

Join to view full profile

Are you Dr. Skolnik?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 55 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

  • Office

    3401 Civic Center Blvd
    Childrens Hospital of Philadelphia Hemonc
    Philadelphia, PA 19104
    Phone+1 215-590-3535
    Fax+1 215-590-3992
  • Is this information wrong?

Summary

  • Dr. Jeffrey Skolnik, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is affiliated with Children's Hospital of Philadelphia.

Education & Training

  • Children's Hospital of Philadelphia
    Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2002 - 2005
  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterResidency, Pediatrics, 1999 - 2002
  • New York University School of Medicine
    New York University School of MedicineClass of 1999

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2002 - 2024

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, Its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
    INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, Its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)November 23rd, 2020
  • INOVIO Presents Clinical Results of Its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (Cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
    INOVIO Presents Clinical Results of Its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (Cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual MeetingNovember 20th, 2020
  • Inovio Receives Authorization from the U.S. FDA to Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine to Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
    Inovio Receives Authorization from the U.S. FDA to Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine to Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)February 10th, 2020
  • Join now to see all

Hospital Affiliations

Dr. Jeffrey Skolnik, Dr. Jeffrey Skolnik, MD, Dr. J Skolnik, Dr. Jeffrey M Skolnik